DE69535673D1 - Mittel zur induktion von apoptosis und zur therapieanwendung - Google Patents

Mittel zur induktion von apoptosis und zur therapieanwendung

Info

Publication number
DE69535673D1
DE69535673D1 DE69535673T DE69535673T DE69535673D1 DE 69535673 D1 DE69535673 D1 DE 69535673D1 DE 69535673 T DE69535673 T DE 69535673T DE 69535673 T DE69535673 T DE 69535673T DE 69535673 D1 DE69535673 D1 DE 69535673D1
Authority
DE
Germany
Prior art keywords
pct
apoptosis
induction
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535673T
Other languages
English (en)
Inventor
Barbara Ann Spruce
Alan Prescott
Angelika Boettger
Deborah Ann Dewar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417444A external-priority patent/GB9417444D0/en
Priority claimed from GB9419285A external-priority patent/GB9419285D0/en
Application filed by University of Dundee filed Critical University of Dundee
Application granted granted Critical
Publication of DE69535673D1 publication Critical patent/DE69535673D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Treatment Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69535673T 1994-08-30 1995-08-30 Mittel zur induktion von apoptosis und zur therapieanwendung Expired - Lifetime DE69535673D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9417444A GB9417444D0 (en) 1994-08-30 1994-08-30 Agents for inducing apoptosis and applications of said agents in therapy
GB9419285A GB9419285D0 (en) 1994-09-23 1994-09-23 Agents for inducing apoptosis and applications of said agents in therapy
PCT/GB1995/002037 WO1996006863A1 (en) 1994-08-30 1995-08-30 Agents for inducing apoptosis and applications of said agents in therapy

Publications (1)

Publication Number Publication Date
DE69535673D1 true DE69535673D1 (de) 2008-02-07

Family

ID=26305534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535673T Expired - Lifetime DE69535673D1 (de) 1994-08-30 1995-08-30 Mittel zur induktion von apoptosis und zur therapieanwendung

Country Status (7)

Country Link
US (1) US5968824A (de)
EP (1) EP0778848B1 (de)
JP (1) JPH10508575A (de)
AT (1) ATE382061T1 (de)
AU (1) AU3352495A (de)
DE (1) DE69535673D1 (de)
WO (1) WO1996006863A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
EP1126832A2 (de) * 1998-10-27 2001-08-29 Yale University Leitung von inkorrekt gefalteten proteinen durch den sekretorischen weg
EP1094063A1 (de) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazole als Bax-Modulatoren
EP1125925A1 (de) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amin-Derivate zur Behandlung von Apoptosis
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
WO2001076457A2 (en) * 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20050031610A1 (en) * 2002-07-19 2005-02-10 Tae-Wan Kim CD44-related fragments, compositions and methods
US7875270B2 (en) * 2002-09-17 2011-01-25 Abbott Medical Optics Inc. Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
US7985405B2 (en) * 2002-09-17 2011-07-26 Jin Jun Zhang Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
AU2004222653C1 (en) * 2003-03-17 2010-10-07 Amo Groningen B.V. New method
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP2006265102A (ja) * 2003-05-08 2006-10-05 Taisho Pharmaceut Co Ltd ＴＧＦβ由来アポトーシス調節方法
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
CN102827826B (zh) * 2012-09-11 2017-07-04 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
WO2017011653A1 (en) * 2015-07-15 2017-01-19 The University Of Florida Research Foundation, Inc. Tissue decellularization methods

Also Published As

Publication number Publication date
EP0778848A1 (de) 1997-06-18
WO1996006863A1 (en) 1996-03-07
EP0778848B1 (de) 2007-12-26
JPH10508575A (ja) 1998-08-25
AU3352495A (en) 1996-03-22
US5968824A (en) 1999-10-19
ATE382061T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
DE69535673D1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE139447T1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
DE69615561T2 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
FI955154A (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE60230807D1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
GR3030032T3 (en) Human il-3 variants.
DE69431046T2 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
TR199901385T2 (xx) Piperidin t�revleri.

Legal Events

Date Code Title Description
8332 No legal effect for de